Equities analysts forecast that Flexion Therapeutics (NASDAQ:FLXN) will post ($1.31) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Flexion Therapeutics’ earnings. The lowest EPS estimate is ($1.46) and the highest is ($1.20). Flexion Therapeutics reported earnings of ($0.75) per share in the same quarter last year, which suggests a negative year over year growth rate of 74.7%. The company is expected to issue its next quarterly earnings results on Thursday, May 3rd.
On average, analysts expect that Flexion Therapeutics will report full-year earnings of ($5.18) per share for the current year, with EPS estimates ranging from ($5.78) to ($4.22). For the next fiscal year, analysts expect that the business will report earnings of ($2.66) per share, with EPS estimates ranging from ($3.72) to ($0.28). Zacks’ EPS calculations are a mean average based on a survey of research firms that follow Flexion Therapeutics.
Flexion Therapeutics (NASDAQ:FLXN) last issued its quarterly earnings results on Thursday, March 8th. The specialty pharmaceutical company reported ($1.38) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.11) by ($0.27). The firm had revenue of $0.36 million during the quarter, compared to the consensus estimate of $1.29 million.
Several equities analysts have recently issued reports on FLXN shares. ValuEngine upgraded Flexion Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, December 31st. Zacks Investment Research downgraded Flexion Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, January 3rd. BidaskClub downgraded Flexion Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, January 20th. Berenberg Bank started coverage on Flexion Therapeutics in a report on Thursday, February 1st. They set a “buy” rating and a $42.00 price objective on the stock. Finally, BMO Capital Markets reissued an “outperform” rating and set a $36.00 price objective (down previously from $37.00) on shares of Flexion Therapeutics in a report on Friday, March 9th. Two analysts have rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the stock. Flexion Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $99.00.
Shares of FLXN opened at $25.04 on Monday. Flexion Therapeutics has a 52-week low of $16.51 and a 52-week high of $32.25. The company has a debt-to-equity ratio of 0.58, a quick ratio of 12.96 and a current ratio of 13.02. The firm has a market capitalization of $947.63, a PE ratio of -6.02 and a beta of 0.83.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Advisory Services Network LLC acquired a new stake in shares of Flexion Therapeutics during the 4th quarter valued at $108,000. SG Americas Securities LLC acquired a new position in Flexion Therapeutics during the 3rd quarter worth about $135,000. Teacher Retirement System of Texas acquired a new position in Flexion Therapeutics during the 4th quarter worth about $245,000. Eaton Vance Management lifted its holdings in Flexion Therapeutics by 37.2% during the 4th quarter. Eaton Vance Management now owns 12,900 shares of the specialty pharmaceutical company’s stock worth $323,000 after buying an additional 3,500 shares during the period. Finally, Berson & Corrado Investment Advisors LLC acquired a new position in Flexion Therapeutics during the 4th quarter worth about $324,000. 94.46% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION NOTICE: “Zacks: Analysts Expect Flexion Therapeutics (FLXN) to Announce -$1.31 Earnings Per Share” was published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this report on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this report can be accessed at https://www.thelincolnianonline.com/2018/04/16/zacks-analysts-expect-flexion-therapeutics-flxn-to-announce-1-31-earnings-per-share.html.
Flexion Therapeutics Company Profile
Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes Zilretta, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.